ECONOMIC IMPACT OF SWITCHING FROM ANTI-TNF THERAPY TO ADALIMUMAB, INFIXIMAB OR OTHER ANTI-TNF COMPARED WITH SWITCHING FROM ANTI-TNF THERAPY TO VEDOLIZUMAB

Chiorean, M; Afzali, A; Cross, R; Zhou, Z; Macaulay, D; Ganguli, A; Wang, A

INFLAMMATORY BOWEL DISEASES, 2018; 24 (): S51